Literature DB >> 18076917

Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease.

Alan M Nieder1, Jill A Mackinnon, Youjie Huang, Lora E Fleming, Leonidas G Koniaris, David J Lee.   

Abstract

PURPOSE: There are no accepted screening recommendations for bladder cancer, although the greatest risk factors for bladder cancer are identifiable and modifiable, ie tobacco exposure. Bladder cancer survival correlates highly with disease stage. We ascertained whether there have been any demographic changes in the stage at presentation and mortality of bladder cancer in Florida during the last 25 years.
MATERIALS AND METHODS: Data from Florida Cancer Data Registry were evaluated on all bladder cancer cases between 1981 and 2004. Cases were coded and analyzed as local, in situ or advanced (regional and distant) disease. Cases were stratified by demographic groups.
RESULTS: The overall incidence of bladder cancer decreased slightly in the last 25 years from 24.3 to 20.5 cases per 100,000 population. Overall white and Hispanic males had an almost 3 and 2-fold incidence of bladder cancer, respectively, compared to that in black males. White females had an almost 2-fold increased incidence compared to black and Hispanic females. Advanced stage bladder cancer decreased minimally in the 25 years. White and black females had the smallest decrease in the annual percent change of advanced bladder cancer. There was only a minimal decrease in bladder cancer mortality rates in black and white but not Hispanic individuals.
CONCLUSIONS: Despite knowledge of the main risk factors for bladder cancer there were only small decreases in the percent of patients presenting with advanced disease in Florida in the last 25 years. Thus, bladder cancer may be an appropriate cancer for increased public awareness campaigns and potentially targeted screening of high risk populations.

Entities:  

Mesh:

Year:  2008        PMID: 18076917     DOI: 10.1016/j.juro.2007.09.082

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Analysis of the Distribution and Temporal Trends of Grade and Stage in Urothelial Bladder Cancer in Northern New England from 1994 to 2004.

Authors:  Alan R Schned; Petra Lenz; Lee E Moore; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Molly Schwenn; Karl T Kelsey; Angeline S Andrew; Dalsu Baris; Margaret R Karagas
Journal:  ISRN Pathol       Date:  2012

2.  A randomized pilot trial of dietary modification for the chemoprevention of noninvasive bladder cancer: the dietary intervention in bladder cancer study.

Authors:  J Kellogg Parsons; John P Pierce; Loki Natarajan; Vicky A Newman; Leslie Barbier; James Mohler; Cheryl L Rock; Dennis D Heath; Khurshid Guru; Michael B Jameson; Hongying Li; Hossein Mirheydar; Michael A Holmes; James Marshall
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-18

3.  Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.

Authors:  Jianfa Li; Chengle Zhuang; Yuchen Liu; Mingwei Chen; Yincong Chen; Zhicong Chen; Anbang He; Junhao Lin; Yonghao Zhan; Li Liu; Wen Xu; Guoping Zhao; Yinglu Guo; Hanwei Wu; Zhiming Cai; Weiren Huang
Journal:  J Exp Clin Cancer Res       Date:  2016-06-21

4.  Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.

Authors:  Myung-Shin Lee; Jisu Lee; Joo Heon Kim; Won Tae Kim; Wun-Jae Kim; Hanjong Ahn; Jinsung Park
Journal:  Oncotarget       Date:  2015-11-24

5.  Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24.

Authors:  Jinsung Park; Dong Wook Shin; Tae-Hwan Kim; Seung Il Jung; Jong Kil Nam; Seung Chol Park; Sungwoo Hong; Jae Hung Jung; Hongwook Kim; Won Tae Kim
Journal:  Cancer Res Treat       Date:  2017-03-10       Impact factor: 4.679

6.  Genomic case report of a low grade bladder tumor metastasis to lung.

Authors:  Marvin J Van Every; Garrett Dancik; Venki Paramesh; Grzegorz T Gurda; David R Meier; Steven E Cash; Craig S Richmond; Sunny Guin
Journal:  BMC Urol       Date:  2018-09-03       Impact factor: 2.264

7.  A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.

Authors:  Chuanzhen Cao; Zhichao Fu; Yueping Liu; Aiping Zhou; Jianfei Wang; Jianzhong Shou
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

8.  KAT8/MOF-Mediated Anti-Cancer Mechanism of Gemcitabine in Human Bladder Cancer Cells.

Authors:  Huihui Zhu; Yong Wang; Tao Wei; Xiaoming Zhao; Fuqiang Li; Yana Li; Fei Wang; Yong Cai; Jingji Jin
Journal:  Biomol Ther (Seoul)       Date:  2021-03-01       Impact factor: 4.634

Review 9.  Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Authors:  Jianfeng Cui; Wenbo Wang; Shouzhen Chen; Pengxiang Chen; Yue Yang; Yunliang Guo; Yaofeng Zhu; Fan Chen; Benkang Shi
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.